Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Operating Margin (2016 - 2025)

Vistagen Therapeutics' Operating Margin history spans 11 years, with the latest figure at 6452.48% for Q4 2025.

  • For Q4 2025, Operating Margin rose 906.0% year-over-year to 6452.48%; the TTM value through Dec 2025 reached 8848.61%, down 128209.0%, while the annual FY2025 figure was 11517.08%, 841360.0% down from the prior year.
  • Operating Margin for Q4 2025 was 6452.48% at Vistagen Therapeutics, up from 7772.87% in the prior quarter.
  • Across five years, Operating Margin topped out at 96633.33% in Q1 2025 and bottomed at 14441.67% in Q2 2024.
  • The 4-year median for Operating Margin is 4666.32% (2021), against an average of 1854.61%.
  • The largest annual shift saw Operating Margin plummeted -1094267bps in 2024 before it soared 10239056bps in 2025.
  • A 4-year view of Operating Margin shows it stood at 2943.85% in 2021, then surged by 35bps to 1918.25% in 2023, then plummeted by -237bps to 6461.54% in 2024, then grew by 0bps to 6452.48% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Operating Margin are 6452.48% (Q4 2025), 7772.87% (Q3 2025), and 6477.05% (Q2 2025).